Journal of Medicinal Chemistry · 2020 · 53 citations · 22 references
PharmacyMedicinal ChemistryOncologyDrug DesignDrug DiscoveryMolecular OncologyEnzyme InhibitionSynthetic LethalitySynthetic Lethality In CancerTargeted Cancer TherapyTargeted TherapyAnticancer Drug ResistanceBrca MutationsBrca2 InactivationBrca2 Synthetic LethalityOlaparib TherapyParp InhibitionParp Inhibitor SensitivityRad51 Protein
-competent and olaparib-resistant cancers, making fully small-molecule-induced synthetic lethality an innovative approach toward unmet oncological needs.
22
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
Talia Golan, Pascal Hammel, Michele Reni et al. · New England Journal of Medicine · 2019 · 2.2K citations · Full text
Medicine, Oncology, Pharmacology +17
Role of BRCA2 in Control of the RAD51 Recombination and DNA Repair Protein
Adelina A. Davies, Jean‐Yves Masson, Michael J. McIlwraith et al. · Molecular Cell · 2001 · 714 citations · Full text
Insights into DNA recombination from the structure of a RAD51–BRCA2 complex
Luca Pellegrini, David S. Yu, Thomas Lo et al. · Nature · 2002 · 704 citations